Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 5/20 | 0.52 |
| ▸ | KDM2A | Q9Y2K7 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | KDM5C | P41229 | 3/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5285987 | 0.85 | RECQL (0.38) | PHF8KDM2AKDM4EKDM5CLMNA | |
| SCHEMBL3253304 | 0.82 | PHF8 (0.55) | PHF8KDM2AKDM4EKDM5CEGLN1 | |
| SCHEMBL23048107 | 0.81 | FAAH (0.43) | PHF8KDM2AKDM4EKDM5CEGLN1 | |
| SCHEMBL25917430 | 0.80 | RECQL (0.54) | ALDH1A1RECQL | |
| SCHEMBL24075889 | 0.79 | ALDH1A1 (0.46) | PHF8KDM2AKDM4EKDM5CLMNA | |
| SCHEMBL19579213 | 0.79 | CA1 (0.44) | PHF8KDM2AKDM4EKDM5C | |
| SCHEMBL15912434 | 0.78 | GNPAT (0.54) | FOLH1 | |
| SCHEMBL31261082 | 0.78 | MAOA (0.40) | LMNAALDH1A1RECQL | |
| SCHEMBL16299451 | 0.78 | NAAA (0.42) | ALDH1A1RECQL | |
| SCHEMBL11761233 | 0.77 | PHF8 (0.55) | PHF8KDM2AKDM4EKDM5CEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109387-A1 | COUPLING OF SULFYDRYL-CONTAINING PEPTIDE AND FLUOROPORPHYRIN AS BIOLOGICAL PROBE | 化学与精细化工广东省实验室 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20200292534-A1 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION | PROMEGA CORPORATION | 2020-09-17 | — | — | US | disclosed |
| US-10648971-B2 | Activation of bioluminescence by structural complementation | PROMEGA CORPORATION (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-10288605-B2 | Activation of bioluminescence by structural complementation | PROMEGA CORPORATION (US) | 2019-05-14 | — | — | US | disclosed |
| US-10184936-B2 | Activation of bioluminescence by structural complementation | PROMEGA CORPORATION (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180196038-A1 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-07-12 | — | — | US | disclosed |
| US-4981773-A | Method for stabilization of organic base substances against light | FUJI PHOTO FILM CO., LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180196038-A1 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION | GLB1, MRPL21, LRBA | PHF8 4695/4885KDM2A 4876/4885KDM4E 4872/4885 |
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | KIF23, KIF5B, KIF2C | PHF8 1034/4885KDM2A 2283/4885KDM4E 1033/4885 |
| US-10184936-B2 | Activation of bioluminescence by structural complementation | GLB1, MRPL21, LRBA | PHF8 4695/4885KDM2A 4876/4885KDM4E 4872/4885 |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | PHF8 1034/4885KDM2A 2283/4885KDM4E 1033/4885 |
| US-10648971-B2 | Activation of bioluminescence by structural complementation | GLB1, MRPL21, LRBA | PHF8 4695/4885KDM2A 4876/4885KDM4E 4872/4885 |
| US-20200292534-A1 | ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATION | GLB1, MRPL21, LRBA | PHF8 4695/4885KDM2A 4876/4885KDM4E 4872/4885 |
| US-10288605-B2 | Activation of bioluminescence by structural complementation | GLB1, MRPL21, LRBA | PHF8 4695/4885KDM2A 4876/4885KDM4E 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.